ArticleClinical rheumatology2017
Macrophage activation syndrome in Still's disease: analysis of clinical characteristics and survival in paediatric and adult patients.
Article in Clinical rheumatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- Systemic juvenile idiopathic arthritis and adult-onset Still's disease are the same disease: evidence from systematic reviews and meta-analyses informing the 2023 EULAR/PReS recommendations for the diagnosis and management of Still's disease.Annals of the rheumatic diseases · 2024Pooled it
- EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease.Annals of the rheumatic diseases · 2024Guideline
- Diagnostic performance of HScore for macrophage activation syndrome complicating Still's disease in adults: a multicentre case-control study.Rheumatology (Oxford, England) · 2026Article
- Advancing Precision Medicine in Adult-Onset Still's Disease: Insights into Biomarkers, Therapies, and COVID-19 Impacts.Mediterranean journal of rheumatology · 2025Review
- Clinical characteristics and prognostic factors in adult macrophage activation syndrome: an observational study in a Chinese cohort.Lupus science & medicine · 2025Observational
- Neutrophilic Urticarial Dermatosis: A Window into Systemic Inflammation and Autoimmune Disorders.Clinical reviews in allergy & immunology · 2025Review
- Macrophage Activation Syndrome in Adult-Onset Still's Disease: Challenges in Early Detection and Management.Cureus · 2025Article
- Still's Disease Onset in Older Adults: Clinical Features, Diagnosis, and Management.Drugs & aging · 2024Review
- Recent advances and evolving concepts in Still's disease.Nature reviews. Rheumatology · 2024Review
- Macrophage Activation Syndrome in the Setting of Rheumatic Diseases.Advances in experimental medicine and biology · 2024Review
- Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Still's disease.Rheumatology (Oxford, England) · 2022Article
- Article
- Associated factors with poor treatment response to initial glucocorticoid therapy in patients with adult-onset Still's disease.Arthritis research & therapy · 2022Article
- Development and Implementation of the AIDA International Registry for Patients With Still's Disease.Frontiers in medicine · 2022Article
- Detection and Prediction of Macrophage Activation Syndrome in Still's Disease.Journal of clinical medicine · 2021Article
- Application of systems biology-based in silico tools to optimize treatment strategy identification in Still's disease.Arthritis research & therapy · 2021Article
- Total metabolic lesion volume of lymph nodes measured byArthritis research & therapy · 2021Article
- Macrophage activation syndrome in systemic lupus erythematosus and systemic-onset juvenile idiopathic arthritis: a retrospective study of similarities and dissimilarities.Rheumatology international · 2021Observational
- Systemic immune-inflammation index combined with ferritin can serve as a reliable assessment score for adult-onset Still's disease.Clinical rheumatology · 2021Article
- An Economic Comparison of Treatment Strategies with Anakinra in Systemic Juvenile Idiopathic Arthritis (sJIA).Open access rheumatology : research and reviews · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Macrophage activation syndrome (MAS) is a reactive form of hemophagocytic lymphohistiocytosis, complicating Still's disease, both in paediatric and adult patients. In this work, we aimed to investigate clinical picture and outcome of Still's disease patients developing MAS. We performed a retrospective analysis of patients, both paediatrics and adults, affected by Still's disease attending our department. During the follow-up, each patient was investigated for MAS occurrence and possible predictors, clinical and laboratory factors, were analysed. We evaluated 50 patients affected by Still's disease, 21 paediatric and 29 adult patients. Ten patients experienced MAS (five adult and five paediatric patients) and its development significantly reduced the survival rate when compared with patients without this complication (p < 0.0001). The analysis of possible predictors showed that high-value systemic score (p = 0.03) and high levels of serum ferritin (p = 0.002) were independently associated with an increased likelihood of MAS. MAS occurrence significantly reduced survival rate in both paediatric and adult patients affected by Still's disease. The high levels of serum ferritin and an elevated systemic score, at the time of diagnosis, were significantly associated with MAS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.